P729: A ‘real-world’ retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitisECCO '18 Vienna
2018
P730: High-dosed intravenous iron replacement therapy does not hinder drug-induced amelioration of disease activity in IBD patients with iron deficiency anaemiaECCO '18 Vienna
2018
P731: The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort studyECCO '18 Vienna
2018
P733: Serum interleukin-6 level predicts future outcomes of infliximab for ulcerative colitisECCO '18 Vienna
2018
P734: Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of lifeECCO '18 Vienna
2018
P735: Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel diseaseECCO '18 Vienna
2018
P736: Point-of-care infliximab quantification in inflammatory bowel disease in daily practiceECCO '18 Vienna
2018
P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable resultsECCO '18 Vienna
2018
P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remittersECCO '18 Vienna
2018
P739: Early use of anti-TNF in Crohn’s disease is associated with higher rate of biological and endoscopic remissionECCO '18 Vienna
2018
P740: Efficacy and safety of vedolizumab in inflammatory bowel disease: Real-life experienceECCO '18 Vienna
2018
P741: Very high rate of tuberculosis complicating infliximab therapy for inflammatory bowel disease despite tuberculosis screening in IndiaECCO '18 Vienna
2018
P742: Long-term outcome of patients with ulcerative colitis and first course of intravenous corticosteroidsECCO '18 Vienna
2018
P743: Ustekinumab use in Crohn´s Disease: Does short-term effectiveness correlate to induction regimen?ECCO '18 Vienna
2018
P744: Therapeutic gain of continued, long-term infliximab therapy in Crohn’s disease patients with response but non-remission after one year of infliximab therapyECCO '18 Vienna
2018
P745: Switching between anti-TNF originator and biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic reviewECCO '18 Vienna
2018